Articles tagged "Calcineurin"

2016 American Transplant Congress
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.
E. Minetti,¹ L. Di Maria,¹ L. Caroti,¹ E. Buti,² P. Carta.¹
¹Nephrology unit, Careggi University Hospital, Florence, Italy; ²Nephrology Unit, Mayer Univerity Hospital, Florence, Italy.
Few data are available on the rate of de novo anti-HLA donor specific antibodies (DSA) with the use of everolimus in kidney transplant recipients.MaterialsWe selected…
2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
A. Aliabadi,¹ J. Goekler,¹ O. Salameh,¹ T. Haberl,¹ B. Steinlechner,² P. Opfermann,² A. Kaider,¹ K. Uyanik-Uenal,¹ G. Laufer,¹ A. Zuckermann.¹
¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Cardiothoracic and Vascular Anaesthisiology, Medical University of Vienna, Vienna, Austria.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…
2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
K. Unagami,¹ M. Okumi,² M. Furusawa,² T. Hirai,² T. Shimizu,² K. Omoto,² M. Inui,² H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…
2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.
A. Zmijewska, J. Chen, J. Zmijewski, R. Mannon.
Medicine, UAB, Birmingham, AL.
Background: CNIs are potent immunosuppressant therapies, but associated with nephrotoxicity manifested by interstitial fibrosis and progressive graft dysfunction. AMPK is a major sensor and regulator…
2016 American Transplant Congress
Novel Nuclear Factor-κB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.
S. Morita,¹ K. Shinoda,¹ S. Tamaki,¹ H. Kono,² Y. Kanno,³ K. Umezawa,⁴ K. Nakagawa,² M. Oya.¹
¹Urology, Keio University School of Medicine, Tokyo, Japan; ²Urology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan; ³Nephrology, Tokyo Medical University, Tokyo, Japan; ⁴Molecular Target Medicine Screening, Aichi Medical University, Nagakute, Aichi, Japan.
Purpose:The nephrotoxicity of the calcineurin inhibitors including cyclosporine is a major problem in the kidney transplantation. We investigated the effect of a novel nuclear factor-κB…
2016 American Transplant Congress
Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
E. Rhone,¹ R. Gehrau,² S. Bontha,² P. Walker,³ C. Dumur,⁴ D. Maluf,² V. Mas.²
¹Pediatrics, University of Virginia, Charlottesville, VA; ²Surgery, University of Virginia, Charlottesville, VA; ³Nephropath, Little Rock, AR; ⁴Pathology, Virginia Commonwealth University, Richmond, VA.
Background:Calcineurin inhibitor nephrotoxicity (CNIT) is a well-known contributor to chronic allograft dysfunction in kidney transplant recipients (KTRs). Pediatric KTRs are particularly at risk given their…
2015 American Transplant Congress
Monitoring Intracellular Tacrolimus Concentration in Kidney Transplant Recipients With Stable Graft Function
E. Bae,¹ S. Han,¹ S. Yang,² J. Park,¹ H. Lee,¹ J. Lee,³ D. Kim,¹ Y. Kim.¹
¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea; ³Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Background: Monitoring the intracellular concentration of immunosuppressive agents can be promising to improve and individualize clinical practice in patients receiving transplantation. However, this issue remains…
2015 American Transplant Congress
Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?
R. Ciria Bru, I. Gómez Luque, M. Cortés Cerisuelo, P. López Cillero, J. O'Grady, M. de la Mata, N. Heaton, J. Briceño Delgado.
Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatology and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatobiliary Surgery and Liver Transplantation, University Reina Sofia Hospital, Córdoba, Spain.
Acute kidney injury(AKI)after liver transplantation (LT) is common.Calcineurin inhibitors(CNI)have to be well-balanced.The aims were analyze the specific effect of CNI on AKI in a cohort…
2015 American Transplant Congress
Cyclosporine Nephrotoxicity Is Associated With Diminished Expression of Heat Shock Protein 27 (HSP27) and Loss of Claudin-2-Dependent Intercellular Adhesion
A. Zmijewska,¹ R. Thuillier,² J. Chen,¹ J. Zmijewski,¹ R. Mannon.¹
¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²INSERM U1082, Poitiers, France.
Although Cyclosporine A (CsA), a calcineurin inhibitor (CNI), is an effective immunosuppressant used to prevent kidney allograft rejection, prolonged administration is frequently associated with kidney…
2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
S.-M. Wang,¹ P.-C. Lee,² J.-D. Lian,³ K.-H. Shu,⁴ S.-T. Wu,⁵ H.-C. Chen,⁶ C.-C. Huang,⁷ M.-S. Wu,⁸ Y.-C. Tian,⁹ Y.-J. Chiang,¹⁰ Y.-T. Chen,¹¹ H.-P. Wang.¹²
¹National Taiwan University Hospital, Taipei, Taiwan; ²National Cheng Kung University Hospital, Tainan, Taiwan; ³Chung Shan Medical University Hospital, Taichung, Taiwan; ⁴Taichung Veteran's General Hospital, Taichung, Taiwan; ⁵TriService General Hospital, Taipei, Taiwan; ⁶Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁷China Medical University Hospital, Taichung, Taiwan; ⁸Taipei Medical University Hospital, Taipei, Taiwan; ⁹ChangGung Memorial Hospital–Taipei, Taipei, Taiwan; ¹⁰ChangGung Memorial Hospital–LinKou, Taoyuan, Taiwan; ¹¹ChangGung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan; ¹²E-Da Hospital, Kaohsiung, Taiwan.
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…